MaaT Pharma Announces Participation in Scientific and Investor Conferences in November
2022年11月8日 - 02:00AM
ビジネスワイヤ（英語）
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French
clinical-stage biotech and a pioneer in the development of
Microbiome Ecosystem TherapiesTM (MET) dedicated to improving
survival outcomes for patients with cancer, today announced the
company’s scientific and management team’s participation in several
scientific and investor conferences in November.
Details of the events are as follows:
Scientific conferences
- November 8-10, 2022 – 9th International Human Microbiome
Consortium (IHMC) Congress: Hervé Affagard, CEO and cofounder
of MaaT Pharma, and Dr. Aurore Duquenoy, R&D specialist at MaaT
Pharma will present three scientific posters at the conference in
Kobe, Japan. Link to the Congress here.
- November 9-11, 2022 – 21st Société Francophone de Greffe de
Moelle et de Thérapie Cellulaire (SFGM-TC) Congress - Booth
#10: Dr. Emilie Plantamura, Head of Clinical Development at
MaaT Pharma and Claire de Condé, Head of Clinical Operations at
MaaT Pharma, will attend the congress in Bordeaux, France and will
be available for discussions at MaaT Pharma’s booth #10.
Link to the event here.
Investor conferences
- November 14, 2022 – 7th annual conference Inve€$tival
Showcase – LSX Leaders in partnership with Jefferies: Siân
Crouzet, Chief Financial Officer of MaaT Pharma and Dr. Carole
Schwintner, Chief Technology Officer of MaaT Pharma will attend the
investor event in London, United Kingdom. More information
available here.
- November 29, 2022 – Investir Day: Siân Crouzet, Chief
Financial Officer of MaaT Pharma and Dr. Savita Bernal, Chief
Business Officer of MaaT Pharma will attend the investor event in
Paris, France. More information available here.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma launched in March
2022 in Europe, a Phase 3 clinical trial for patients with acute
GvHD, following the achievement of its proof of concept in a Phase
2 trial. Its powerful discovery and analysis platform, gutPrint®,
supports the development and expansion of its pipeline by
determining novel disease targets, evaluating drug candidates, and
identifying biomarkers for microbiome-related conditions. The
company’s Microbiome Ecosystem Therapies are produced through a
standardized cGMP manufacturing and quality control process to
safely deliver the full diversity of the microbiome, in liquid and
oral formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice.
MaaT Pharma is the first company developing microbiome-based
therapies listed on Euronext Paris (ticker: MAAT).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221107005319/en/
MaaT Pharma – Investor Relations Hervé AFFAGARD
Co-Founder and CEO Siân Crouzet, COO/ CFO +33 4 28 29 14 00
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 07 55 25 36
media@maat-pharma.com
Trophic Communications – Corporate and Medical
Communications Jacob VERGHESE or Gretchen SCHWEITZER +49 89
2070 89831 maat@trophic.eu
Maat Pharma (EU:MAAT)
過去 株価チャート
から 2 2023 まで 3 2023
Maat Pharma (EU:MAAT)
過去 株価チャート
から 3 2022 まで 3 2023
